Mattawan, Mich. – MPI Research announced today that James F. Reindel, DVM, PhD, DACVP has been appointed Scientific Director of Pathology.

“Dr. Reindel brings invaluable expertise to this position,” said Daniel Patrick, MPI Research Director of Pathology. “With over 25 years of toxicologic pathology experience, and a majority of his career in leadership positions at two major pharmaceutical companies, he represents an outstanding addition to our team.”

As Scientific Director of Pathology, Dr. Reindel will be involved in pathology quality control, including pathology peer reviews, and scientific reviews of pathology reports, study proposals, and protocols. Additionally, he will be assisting in business development efforts and strategic sales planning.

“The addition of Dr. Reindel to the MPI Research team further expands our knowledge base and capabilities, allowing us to provide high quality service and expert counsel to our Sponsors,” said Patrick.

Throughout his career, Dr. Reindel has garnered extensive, broad-based toxicologic pathology and drug development knowledge involving both small molecule and biologics. Prior positions include Director of Pathology at Amgen in Seattle, and several leadership positions within Pfizer. Dr. Reindel is well versed in the functional aspects of pathology practices for regulated safety studies conducted in-house and in conjunction with various contract research organizations.

Dr. Reindel received his DVM and PhD at Michigan State University and has held a position as an adjunct professor for the University since 1991. He has authored numerous peer-reviewed articles and served as manuscript reviewer for professional journals including Veterinary Pathology and the Toxicologic Pathology. He is an active member of the American College of Veterinary Pathologists (ACVP) and the Society of Toxicologic Pathologists (STP) among various other professional societies.